Drug Profile

Claseprubart - Dianthus Therapeutics

Alternative Names: DNTH 103

Latest Information Update: 02 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dianthus Therapeutics
Class Antianaemics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Complement C1s inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myasthenia gravis
New Molecular Entity Yes

Highest Development Phases

Phase III Chronic inflammatory demyelinating polyradiculoneuropathy; Myasthenia gravis
Phase II Multifocal motor neuropathy

Most Recent Events

29 Jun 2026 Phase-III clinical trials in Myasthenia gravis (SC) (NCT07647510)
22 Jun 2026 Dianthus Therapeutics plans a phase III EMERGE trial for Myasthenia gravis in July 2026 (SC, Injection) (NCT07647510)
06 May 2026 Claseprubart - Dianthus Therapeutics receives Orphan Drug status for Myasthenia gravis in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com